Signature of click chemistry in exosome modification for cancer therapeutic

Abstract

Exosomes, small extracellular vesicles secreted by cells, have gained attention as potential therapeutic agents due to their natural ability to deliver biomolecules and traverse biological barriers. However, their limited targeting specificity and payload capacity necessitate modifications for improved therapeutic efficacy. Click chemistry, known for its high specificity, efficiency, and mild reaction conditions, offers an innovative solution for modifying exosomal surfaces. This technique enables precise attachment of targeting ligands, imaging agents, and therapeutic molecules, enhancing the targeting, delivery, and overall effectiveness of exosome-based therapies. By addressing cancer heterogeneity, click chemistry-modified exosomes can target diverse cancer cell populations within tumors, improving treatment specificity and reducing drug resistance. The development of copper-free click chemistry, such as strain-promoted azide-alkyne cycloaddition (SPAAC), minimizes toxicity, ensuring biocompatibility and safety. As research progresses, this approach holds great promise for personalized and effective cancer treatment, paving the way for next-generation therapeutics and diagnostics.

Keywords

biocompatibility / click chemistry / cancer heterogeneity / exosomes / targeted therapy

References

[1] American Cancer Society. American Cancer Society releases latest cancer statistics, launches initiative to address prostate cancer resurgence and disparities. 2023. Available from: https://pressroom.cancer.org/FactsandFigures23

[2] Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA Cancer J Clin. 2023;73(1):17-48.

[3] Lopez K, Lai SWT, Lopez Gonzalez EJ, Dávila RG, Shuck SC. Extracellular vesicles: a dive into their role in the tumor microenvironment and cancer progression. Front Cell Dev Biol. 2023;11:1154576.

[4] Dai J, Su Y, Zhong S, et al. Exosomes: key players in cancer and potential therapeutic strategy. Sig Transduct Target Ther. 2020;5:145.

[5] Tai YL, Chen KC, Hsieh JT, Shen TL. Exosomes in cancer development and clinical applications. Cancer Sci. 2018;109(8):2364-2374.

[6] Kim HI, Park J, Zhu Y, et al. Recent advances in extracellular vesicles for therapeutic cargo delivery. Exp Mol Med. 2024;56:836-849.

[7] Wu M, Wang M, Jia H, Wu P. Extracellular vesicles: emerging anti-cancer drugs and advanced functionalization platforms for cancer therapy. Drug Deliv. 2022;29(1):2513-2538.

[8] Smyth T, Petrova K, Payton NM, et al. Surface functionalization of exosomes using click chemistry. Bioconjug Chem. 2014;25(10):1777-1784.

[9] Pineda-Castañeda HM, Rivera-Monroy ZJ, Maldonado M. Copper(I)-catalyzed alkyne-azide cycloaddition (CuAAC) “click” reaction: a powerful tool for functionalizing polyhydroxylated platforms. ACS Omega. 2023;8(4):3650-3666.

[10] Li Li, Zhang Zhiyuan. Development and applications of the copper-catalyzed azide-alkyne cycloaddition (CuAAC) as a bioorthogonal reaction. Molecules. 2016;21(10):1393.

[11] N'Diaye ER, Orefice NS, Ghezzi C, Boumendjel A. Chemically modified extracellular vesicles and applications in radiolabeling and drug delivery. Pharmaceutics. 2022;14(3):653.

[12] Zheng Z, Li Z, Xu C, Guo B, Guo P. Folate-displaying exosome mediated cytosolic delivery of siRNA avoiding endosome trapping. J Control Release. 2019:43-49. 311–312.

[13] Liang Y, Duan L, Lu J, Xia J. Engineering exosomes for targeted drug delivery. Theranostics. 2021;11(7):3183-3195.

[14] Dhar R, Devi A. Engineered cell versus modified exosomes in cancer therapy. Clin Transl Disc. 2024:e320.

[15] Ashique Sumel, Anand Krishnan. Radiolabelled extracellular vesicles as imaging modalities for precise targeted drug delivery. Pharmaceutics. 2023;15(5):1426.

[16] Aafreen S, Feng J, Wang W, Liu G. Theranostic extracellular vesicles: a concise review of current imaging technologies and labeling strategies. Extracell Vesicles Circ Nucl Acids. 2023;4(1):107-132.

[17] Huda MN, Nafiujjaman M, Deaguero IG, et al. Potential use of exosomes as diagnostic biomarkers and in targeted drug delivery: progress in clinical and preclinical applications. ACS Biomater Sci Eng. 2021;7(6):2106-2149.

[18] Asfiya R, Xu L, Paramanantham A, et al. Physio-chemical modifications to re-engineer small extracellular vesicles for targeted anticancer therapeutics delivery and imaging. ACS Biomater Sci Eng. 2024;10(2):697-722.

[19] Tenchov R, Sasso JM, Wang X, Liaw WS, Chen CA, Zhou QA. Exosomes─nature's lipid nanoparticles, a rising star in drug delivery and diagnostics. ACS Nano. 2022;16(11):17802-17846.

[20] Zhang KL, Wang YJ, Sun J, et al. Artificial chimeric exosomes for anti-phagocytosis and targeted cancer therapy. Chem Sci. 2018;10(5):1555-1561.

[21] Jung I, Shin S, Baek MC, et al. Modification of immune cell-derived exosomes for enhanced cancer immunotherapy: current advances and therapeutic applications. Exp Mol Med. 2024;56:19-31.

[22] Rezaie J, Feghhi M, Etemadi T. A review on exosomes application in clinical trials: perspective, questions, and challenges. Cell Commun Signal. 2022;20(1):145.

[23] Morales RT, Ko J. Future of digital assays to resolve clinical heterogeneity of single extracellular vesicles. ACS Nano. 2022;16(8):11619-11645.

[24] Kim E, Koo H. Biomedical applications of copper-free click chemistry: in vitro, in vivo, and ex vivo. Chem Sci. 2019;10(34):7835-7851.

[25] Fisher R, Pusztai L, Swanton C. Cancer heterogeneity: implications for targeted therapeutics. Br J Cancer. 2013;108(3):479-485.

[26] Kalluri R, LeBleu VS. The biology, function, and biomedical applications of exosomes. Science. 2020;367(6478):eaau6977.

[27] Liang Y, Duan L, Lu J, Xia J. Engineering exosomes for targeted drug delivery. Theranostics. 2021;11(7):3183-3195.

RIGHTS & PERMISSIONS

2024 2024 The Author(s). Clinical and Translational Discovery published by John Wiley & Sons Australia, Ltd on behalf of Shanghai Institute of Clinical Bioinformatics.